Lyme Disease Diagnostic Market Size (2023 - 2030)

The global Lyme disease diagnostic market size was worth USD 837.2 million in 2022 and is expected to reach 1154.26 million by 2030 with a CAGR of 7.2% from 2023 - 2030.

Lyme is a bacterial infection caused by Borrelia and spreads over the human body through tick bites. The symptoms associated with Lyme disease are depression, skin diseases like rashes, fatigue, and fever. The disease is treated at the initial stage using antibiotics and if the disease is left untreated, affects the joints, heart, and central nervous system (CNS).

Lyme disease is caused by the bacteria Borreliosis, which is the most common and quickly spreading tick-borne disease globally. 

The sudden outbreak of the novel coronavirus (COVID-19) has affected millions of people globally resulting in death. Many businesses including healthcare are affected during the pandemic period. Many healthcare professionals concentrated on combating the virus. Tele consultations and video consultations have come into existence as patients stopped visiting their concerned doctors. Same way, the pandemic has created a negative impact on Lyme disease during the first half of the COVID-19. Later, after the lockdown, people started visiting the hospitals with all necessary safety precautions taken. Post-COVID, there is an increase in the vaccination number for the Lyme disease diagnosis and people feel safe and more protective in visiting the diagnostic centers fueling the market growth. 

Market Drivers

Increasing patient population

There is an increase in the patient population diagnosed with Lyme disease leading to the growing demand for diagnostic tests driving the Lyme disease diagnostic market growth. The existence of well-developed infrastructure propels market growth. The government has taken some initiatives to improve the healthcare amenities; key players are efficiently making efforts for research and development activities providing opportunities for the Lyme disease diagnostics market. 

Market Restrains

People are not aware of the disease and the inefficiency of Lyme disease obstructs the Lyme disease diagnostics market growth globally.

LYME DISEASE DIAGNOSTIC MARKET REPORT COVERAGE

CLICK HERE TO DOWNLOAD SAMPLE

Segmentation Analysis

The research report on the global Lyme disease diagnostic market has been segmented and sub-segmented based on diagnostic technology, and end-user.

Lyme Disease Diagnostic Market - By Diagnostic Technology

• Serological Test
• Nucleic acid amplification techniques
• Urine Antigen Tests
• Lymphocytic Transformation Test
• Immunofluorescent Staining
• PCR Analysis
• Others

By diagnostic technology, the serological test segment is dominating the Lyme disease diagnostic market globally. The serological test mainly focuses on puffing out the antibodies generated in response to antigens in the body of an infected person. The serological test involves ELISA, precipitation, agglutination, and western blot procedures that identify infectious diseases. 

The PCR analysis segment is the second segment that is growing with the largest share. The segment growth owes to the robust empathy of PCR in identifying infection with Borrelia causing Lyme disease. 

The nucleic acid amplification technique is said to have the quickest CAGR rate throughout the forecast period. The growth is due to repeated use in labs to produce different sources of clinical specimens. 

Lyme Disease Diagnostic Market - By End-User

• Hospitals
• Pathology labs
• Pharmaceutical Industries and Clinical Research Institute

By end-user, the hospital's segment is accounted for holding the largest share in the Lyme disease diagnostic market. The easy availability of commercial diagnostic kits for identifying Lyme disease, an increasing number of hospitals with skilled professionals, and well-structured healthcare infrastructure boosts the market growth. 

Regional Analysis

North America is dominating the Lyme disease diagnostic market globally. The region is projected to continue its dominance over the upcoming years. Nearly 3,00,000 people are diagnosed with Lyme disease every year in North America, as per the Centers for Disease Control and Prevention (CDC). The market growth in the region owes to growing expenses in the healthcare sector, and the initial availability of new products. The U.S Lyme disease diagnostic market is driven by factors like a huge patient population and the growing number of Lyme disease diagnostic service providers. Every year in the U.S., around 40,000 cases are recorded, and Lyme disease is the most common vector-borne disease. 80% of the population in eastern Canada is living with Lyme disease. 

Europe is considered to rank second in the Lyme disease diagnostics market. Countries like Germany, UK, France, Italy contribute a major share in the global Lyme disease diagnostics market.

Asia-Pacific region is projected to gain substantial growth in the global Lyme disease diagnostics market. The growth in the region is attributed to growing occurrences of Lyme diseases, rising need for superior diagnostic tests for diseases. 

Latin America is the second leading region after Asia-Pacific to grow with the quickest CAGR growth rate throughout the historical period. Brazil, Mexico, and the Rest of Latin America support the Lyme disease diagnostics market grow forward. Brazil is expected to lead the market in the region. 

The Lyme disease diagnostics market in the Middle East & African region is anticipated to have tremendous growth in the forthcoming years. UAE is said to dominate the market in the region. 

Key Market Players

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Boulder Diagnostics
• T2 Biosystems, Inc.
• Abbott
• Oxford Immunotec Global PLC
• Quidel Corporatio
• Affymetrix Inc.
• Hoffmann-La Roche Ltd
• Graphene Frontiers

In September 2018, T2 Biosystems, Inc. introduced a new T2Lyme Panel diagnostic procedure for identifying the Lyme disease-0causing bacteria. 

In July 2022, PerkinElmer combined with EverlyWell for boosting the innovation in and obtainability of consumer-initiated health testing. The association involves Lyme disease and food sensitivity tests. 

Recent Market Developments

• On April 13, 2022, Quidel Corporation associated with the Bay Area Lyme (BAL) Foundation, helping people to be more aware of their health condition.
• On June 13, 2018, the U.S FDA has approved the Gold Standard Diagnostics Borrelia bugdorferi IgG/IgM ELISA assay.